74788-46-8

Usage

Uses

Used in Scientific Research:
1-(4-chlorophenyl)propan-1-amine is used as a research chemical for studying the neurochemistry and pharmacology of neurotransmitters such as serotonin and dopamine. Its psychoactive properties allow researchers to gain insights into the mechanisms of action and interactions of these neurotransmitters within the central nervous system.
Used in Neurotransmitter Studies:
PCA is used as a tool in neurotransmitter studies to understand the effects of psychoactive substances on the brain's chemical messengers. This helps in the development of treatments for various neurological and psychiatric disorders.
Used in Toxicology Research:
Due to its potential neurotoxic effects, 1-(4-chlorophenyl)propan-1-amine is utilized in toxicology research to explore the impact of psychoactive substances on brain health and to develop strategies for mitigating their harmful effects.
Used in Regulatory and Forensic Analysis:
As a controlled substance with abuse potential, para-Chloroamphetamine is used in regulatory and forensic analysis to detect and monitor its presence in cases of substance abuse or illegal distribution. This aids in enforcing laws and regulations related to controlled substances.

InChI:InChI=1/C9H12ClN/c1-2-9(11)7-3-5-8(10)6-4-7/h3-6,9H,2,11H2,1H3

Upstream product

• 6285-05-8 4'-chloropropiophenone 
• 540-69-2 ammonium formate 
• 925-90-6 ethylmagnesium bromide 
• 85654-07-5 N-(4-chlorobenzylidene)-N-(1,1,1-trimethylsilyl)amine 
• 56962-09-5 1-(4-chlorophenyl)-N-hydroxypropan-1-imine 
• 104-88-1 4-chlorobenzaldehyde 

Downstream Products

• 74787-93-2 3-[1-(4-Chloro-phenyl)-propyl]-1-(2-hydroxy-ethyl)-1-methyl-thiourea 
• 132361-85-4 (Z)-3-[1-(4-Chloro-phenyl)-propylamino]-but-2-enoic acid methylamide 
• 1143532-27-7 4-amino-N-(1-(4-chlorophenyl)propyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide 

Relevant academic research and scientific papers

MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF

The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.

The Synthesis of Primary Amines through Reductive Amination Employing an Iron Catalyst

The reductive amination of ketones and aldehydes by ammonia is a highly attractive method for the synthesis of primary amines. The use of catalysts, especially reusable catalysts, based on earth-abundant metals is similarly appealing. Here, the iron-catalyzed synthesis of primary amines through reductive amination was realized. A broad scope and a very good tolerance of functional groups were observed. Ketones, including purely aliphatic ones, aryl–alkyl, dialkyl, and heterocyclic, as well as aldehydes could be converted smoothly into their corresponding primary amines. In addition, the amination of pharmaceuticals, bioactive compounds, and natural products was demonstrated. Many functional groups, such as hydroxy, methoxy, dioxol, sulfonyl, and boronate ester substituents, were tolerated. The catalyst is easy to handle, selective, and reusable and ammonia dissolved in water could be employed as the nitrogen source. The key is the use of a specific Fe complex for the catalyst synthesis and an N-doped SiC material as catalyst support.

Substituent effects on chiral resolutions of derivatized 1-phenylalkylamines by heptakis(2,3-di-O-methyl-6-O-tert-butyldimethylsilyl)-β-cyclodextrin GC stationary phase

Chiral resolutions of trifluoroacetyl-derivatized 1-phenylalkylamines with different type and position of substituent were investigated by capillary gas chromatography by using heptakis(2,3-di-O-methyl-6-O-tert-butyldimethylsilyl)-β-cyclodextrin diluted in OV-1701 as a chiral stationary phase. The influence of column temperature on retention and enantioselectivity was examined. All enantiomers of meta-substituted analytes as well as fluoro-substituted analytes could be resolved. Temperature had a favorable influence on enantioselectivity for small amines with substituents at the ortho-position. The type of substituent at the stereogenic center of amines also had a crucial effect as the ethyl group led to poor enantioseparation. Among all analytes studied, trifluoroacetyl-derivatized 1-(2′-fluorophenyl)ethylamine exhibited baseline resolution with the shortest analysis time.

PROCESS FOR THE PREPARATION OF CHIRAL AMINES FROM PROCHIRAL KETONES

There is provided a method for the preparation of an enantiomerically enriched amine from a prochiral ketone.

NITROGENATED HETEROCYCLIC COMPOUND

The present invention provides a compound having a PDE2A selective inhibitory action, which is useful as an agent for the prophylaxis or treatment of schizophrenia, Alzheimer's disease and the like. The present invention is a compound represented by the formula (1): wherein each symbol is as described in the specification, or a salt thereof.

CYCLOBUTENEDIONE DERIVATIVES

The present invention relates to compounds of the formula (I): to pharmaceutically acceptable salts therefore and to pharmaceutically acceptable solvates of said compounds and salts, wherein the substituents are defined herein; to compositions containing such compounds; and to the uses of such compounds in the treatment of various diseases, particularly inflammatory conditions.

2-Mercaptoimidazoles, a new class of potent CCR2 antagonists

We describe the synthesis and SAR of a new class of CCR2 antagonists based on a 2-mercaptoimidazole scaffold. The initial lead 1a was optimized to the 3,4-disubstituted analogues 1p-(S) and 1q-(S), which have IC50 values in the MCP-1 induced Ca

Pharmacological studies of 1-(p-chlorophenyl)propanol and 2-(1-hydroxy-3-butenyl)phenol: Two new non-narcotic analgesics designed by molecular connectivity

Molecular topology has been applied to the design of new analgesic drugs. Linear discriminant analysis and connectivity functions were used to design two potentially suitable drugs which were synthesized and tested for analgesic properties by the acetic acid-induced abdominal constriction test in mice and the tail-flick test in rats. In mice, the compound 1-(p-chlorophenyl)propanol showed higher analgesic activity, both intraperitoneally and orally, than acetylsalicylic acid. 2-(1-Hydroxy-3-butenyl)phenol exhibited a lesser protective effect (70% of that shown by acetylsalicylic acid). In rats, acetylsalicylic acid gave the greatest protection against pain when administered intraperitoneally, while 1-(p-chlorophenyl)propanol was the most active orally. The 2-(1-hydroxy-3-butenyl)phenol, both intraperitoneally and orally, showed the least protective effect. These results demonstrated the peripheral analgesic properties of the selected compounds, thus confirming the validity of the molecular design method.